MIDGE Patent granted by European Patent Office
Mologen announces the issuance of the basic patent covering the MIDGE minimalistic vector technology. The patent will be issued for Europe as EP0941318 and covers the design principle of Mologen´s vectors used for genetic vaccination and gene therapy. Another patent covering the vector systems production has been issued in Germany, and is currently pending at the international office.
From Mologen´s perspective, the issuance of the MIDGE patent is a major step with regard to the extension of our IP portfolio and the protection of our basic technology.
MIDGE is a registered trademark of MOLOGEN.
For further information: [email protected]